Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 0.73 |
| ▸ | HTR2C | P28335 | 6/20 | 0.73 |
| ▸ | HTR1A | P08908 | 4/20 | 0.71 |
| ▸ | HTR2A | P28223 | 4/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.71 |
| ▸ | HTR2B | P41595 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | HTR1B | P28222 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.71 |
| ▸ | HTR3B | O95264 | 1/20 | 0.71 |
| ▸ | DRD1 | P21728 | 1/20 | 0.71 |
| ▸ | HTR1E | P28566 | 1/20 | 0.71 |
| ▸ | HTR1F | P30939 | 1/20 | 0.71 |
| ▸ | HTR7 | P34969 | 1/20 | 0.71 |
| ▸ | DRD3 | P35462 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | HTR3A | P46098 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6987521 | 0.90 | SLC6A4 (0.71) | HTR1DHTR2CHTR1AHTR2ACYP2D6 | |
| SCHEMBL6978810 | 0.89 | SLC6A4 (0.69) | HTR1DHTR2CHTR1AHTR2ACYP2D6 | |
| SCHEMBL6980070 | 0.87 | SLC6A4 (0.68) | HTR1DHTR2CHTR1AHTR2ACYP2D6 | |
| SCHEMBL5017513 | 0.86 | HTR2C (0.71) | HTR1DHTR2CHTR1AHTR2ACYP2D6 | |
| SCHEMBL15920450 | 0.86 | HTR2C (0.74) | HTR1DHTR2CHTR1AHTR2ACYP2D6 | |
| SCHEMBL266613 | 0.86 | NPSR1 (0.68) | HTR1DHTR2CHTR1AHTR2ACYP2D6 | |
| SCHEMBL7002494 | 0.86 | HTR2C (0.77) | HTR1DHTR2CHTR1AHTR2ACYP2D6 | |
| SCHEMBL29355422 | 0.85 | HTR1D (1.00) | HTR1DHTR2CHTR1AHTR2ACYP2D6 | |
| SCHEMBL8891077 | 0.85 | HTR1D (1.00) | HTR1DHTR2CHTR1AHTR2ACYP2D6 | |
| SCHEMBL14907356 | 0.85 | HTR2C (0.72) | HTR1DHTR2CHTR1AHTR2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102209521-A | Hair care compositions, methods and articles of commerce that can enhance the appearance of thicker and fuller hair | PROCTER & GAMBLE | 2011-10-05 | — | — | CN | claimed |
| WO-2025099444-A1 | N-Acetylserotonin (NAS) Analogues | Beckley Psytech Limited (GB) | 2025-05-15 | — | — | WO | disclosed |
| WO-2024008341-A1 | SEROTONIN ANALOGUES FOR USE IN TREATING METALLOPTOSIS-ASSOCIATED DISORDERS | INSTITUT CURIE (FR) | 2024-01-11 | — | — | WO | disclosed |
| US-11787783-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
| WO-2023152642-A1 | OPHTHALMIC COMPOSITIONS AND METHODS THEREOF | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-08-17 | — | — | WO | disclosed |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TEMPLE OTORONGO LLC (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2023079427-A1 | OPHTHALMIC COMPOSITIONS AND METHODS THEREOF | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023023298-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PSILOSTERICS, LLC (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2021242849-A1 | ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME | THE ROCKEFELLER UNIVERSITY (US) | 2021-12-02 | — | — | WO | disclosed |
| US-10697985-B2 | Method for detecting small molecules in a sample | IMMUSMOL SAS (FR) | 2020-06-30 | — | — | US | disclosed |
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-10-29 | — | — | US | disclosed |
| US-9073851-B2 | Compositions and methods for treating cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2014091467-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATION | KANDULA MAHESH (IN) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014060925-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISEASES | KANDULA MAHESH (IN) | 2014-04-24 | — | — | WO | disclosed |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| CN-102209521-A | Hair care compositions, methods and articles of commerce that can enhance the appearance of thicker and fuller hair | PROCTER & GAMBLE | 2011-10-05 | — | — | CN | disclosed |
| EP-1827427-B1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARM BV (NL) | 2008-07-23 | — | — | EP | disclosed |
| EP-1268422-A1 | INDOLES FOR TREATING DISEASES THAT CAN BE TREATED USING THYROID HORMONES | Bayer Aktiengesellschaft (DE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001070687-A1 | INDOLES FOR TREATING DISEASES THAT CAN BE TREATED USING THYROID HORMONES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | HDGF, HCCS, CCNC | HTR1D 1044/4885HTR2C 380/4885HTR1A 152/4885 |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | HDGF, HCCS, CCNC | HTR1D 1044/4885HTR2C 380/4885HTR1A 152/4885 |
| US-11787783-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | HTR1D 1097/4885HTR2C 686/4885HTR1A 1131/4885 |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TPH1, TPH2, SYMPK | HTR1D 13/4885HTR2C 15/4885HTR1A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.